AKESO(HK:09926) Zhi Tong Cai Jing·2025-11-12 02:05Core Viewpoint - 康方生物's stock rose nearly 5%, reaching 119.9 HKD with a trading volume of 310 million HKD, following the announcement of the completion of the first patient dosing in a Phase I clinical trial for its personalized mRNA vaccine AK154 for postoperative adjuvant treatment of pancreatic cancer [1] Group 1: Company Developments - 康方生物 announced that its first self-developed personalized mRNA vaccine, AK154, has completed the first patient dosing in a Phase I clinical trial [1] - AK154 is the company's first mRNA drug to enter clinical stages, marking a significant breakthrough in the mRNA technology field after establishing advantages in multi-specific antibodies and antibody-drug conjugates [1] - The vaccine is developed based on an mRNA technology platform, utilizing tumor tissue sequencing and algorithms to select high-affinity immunogenic gene mutations for the preparation of specific mRNA vaccine sequences [1] Group 2: Clinical Trial Insights - AK154 aims to reverse the "cold tumor" characteristics of pancreatic cancer and is expected to enhance anti-tumor immunity when used in combination with immune dual antibodies [1] - The combination of AK154 with either the PD-1/CTLA-4 dual antibody or the PD-1/VEGF dual antibody is anticipated to produce a synergistic effect, further boosting the immune response against tumors [1]